Related Experiment Video
Updated: Apr 30, 2026
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Radiation therapy for Hodgkin lymphoma
Insights
Long-term cardiac complications, including heart failure and coronary artery disease, are a significant risk for Hodgkin lymphoma survivors treated with radio(chemo)therapy. Cardiovascular event risk is 2-7 times higher, necessitating vigilant cardiac monitoring.
Area of Science:
- Cardiology
- Oncology
- Radiotherapy
Background:
- Radio(chemo)therapy is a standard treatment for Hodgkin lymphoma.
- Long-term survivors of Hodgkin lymphoma face significant health challenges.
- Cardiac complications are a known, serious side effect of chest irradiation.
Observation:
- Chest irradiation for Hodgkin lymphoma can lead to various long-term cardiac issues.
- These complications include coronary artery disease, arrhythmias, valvular disease, pericardial disease, cardiomyopathy, and heart failure.
- The severity of myocardial damage correlates with radiation dose, volume, and technique.
Findings:
- Patient age at treatment and pre-existing cardiac risk factors influence the extent of cardiac damage.
- The relative risk of cardiovascular events is elevated 2-fold to 7-fold compared to the general population.
- Clinical presentations range from asymptomatic conditions to end-stage coronary or valvular disease.
Implications:
- Survivors require lifelong cardiac surveillance to detect and manage potential complications early.
- Understanding dose-volume effects and patient-specific factors can help personalize treatment strategies.
- Further research into cardioprotective measures during radiotherapy is crucial for improving long-term outcomes.
Abstract:
The long-term cardiac complications of radio(chemo)therapy for Hodgkin lymphoma include coronary artery disease, cardiac arrhythmias, valvular disease, pericardial disease, cardiomyopathy and heart failure. The extent of myocardial damage after radiotherapy is dependent on the dose, the volume and the technique of chest irradiation. Also, patient-specific factors, such as the age of the patient at the time of treatment and the presence of classical cardiac risk factors are supposed to be important. The relative risk of cardiovascular events is estimated to be 2 to 7 times higher than the general population. The patient's clinical picture can vary from asymptomatic to an acute presentation of end-stage coronary artery or valvular disease.
